WO1981002671A1 - Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration - Google Patents

Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration Download PDF

Info

Publication number
WO1981002671A1
WO1981002671A1 PCT/DK1981/000027 DK8100027W WO8102671A1 WO 1981002671 A1 WO1981002671 A1 WO 1981002671A1 DK 8100027 W DK8100027 W DK 8100027W WO 8102671 A1 WO8102671 A1 WO 8102671A1
Authority
WO
WIPO (PCT)
Prior art keywords
asa
active ingredient
pharmaceutically acceptable
disease
crohn
Prior art date
Application number
PCT/DK1981/000027
Other languages
English (en)
French (fr)
Inventor
S Halskov
Original Assignee
Ferring Farma Lab
S Halskov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Farma Lab, S Halskov filed Critical Ferring Farma Lab
Publication of WO1981002671A1 publication Critical patent/WO1981002671A1/en
Priority to US07/371,123 priority Critical patent/US5013727A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Definitions

  • compositions and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration are provided.
  • the present invention relates to a pharmaceutical com ⁇ position useful for the treatment of colitis ulcerosa and Crohn's disease, currently denominated "inflammatory bowel diseases” (IBD) .
  • the invention also relates to a method for the treatment of IBD.
  • Colitis ulcerosa is a chronic inflammatory disease of the colon of unknown etiology. In its acute stages it resembles an infectious disease, but no microorganism has been definitively established as its cause. The disease causes inflammations of the mucosa of the colon, with extension to the submucosa in severe cases. Typi ⁇ cally, not only the colon, but also the rectum is attacked, but only rarely is the ileuin involved. The ulcer formation and its extent vary with the develop ⁇ mental stage of the disease, but can often be detected macroscopically (sigmoidoscopy and colonoscopy) . For an exhaustive discussion of the disease and the various surgical and medical methods of treatment reference is made to "Ulcerative colitis", Goodman & Sparberg, Wiley, New York 1978.
  • Crohn's disease also known as regional enteritis or colitis granulomatosa, which is also discussed by Goodman & Sparberg, is most frequently located in the small intestine (small bowel) , especial ⁇ ly in the ileum, but may also affect the jejunum and any part of the colon, including the rectum. In the latter case the differentiation of Crohn's disease from ulcerative colitis give rise to great diagnostic problems. Generally, the inflammatory reactions differ
  • corticosteroids e.g. prednisone, prednisolone and hydrocortisone.
  • a drug recently pro- posed is 6 ⁇ -fluoro-li ⁇ -hydroxy-3,20-dioxa-16 ⁇ -methyl- l,4- ⁇ regnadiene-21-carboxylic acid butyl ester, cf. PCT Application No. WO 80/00122.
  • SASP sulfazalazine
  • SP sulfa- pyridine
  • 5-ASA 5-aminosalicylic acid
  • Azad Khan et al., op. cit. who compared SASP, SP and 5-ASA administered rectally and concluded that the therapeutically active moiety was 5-ASA and that SP only acts as a "carrier" to ensure that 5-ASA is not released until it has reached the colon.
  • Azad Khan chose rectal administration and not oral admini ⁇ stration, which is the ordinary mode for SASP, because previous studies of absorption in healthy patients had shown that free 5-ASA is absorbed- from the small bowel in particular the jejunum, which was considered inappropriate as it prevented topical action in the colon.
  • the object of the present invention is to provide an improved pharmaceutical composition useful for the treatment of colitis ulcerosa or Crohn's disease by oral administration and a method for such treatment.
  • the invention is based on the fact that the rooted prejudice against oral administration of 5-ASA as free acid has surprisingly been overcome because in this mode, too, 5-ASA and its salts and esters have a useful therapeutic effect on colitis ulcerosa, in particular when administered in the form of sustained- release tablets.
  • the invention relates to a pharmaceutical composition useful for the treatment of Colitis ulcerosa or Crohn's disease by oral administration, which com ⁇ prises as essential active ingredient an effective amount of 5-aminosalicylic acid or a pharmaceutically acceptable salt or ester thereof in admixture with a pharmaceutically acceptable carrier.
  • the salts of 5-ASA may be acid addition salts, in par ⁇ ticular the hydrochloride, but any pharmaceutically acceptable, non-toxic organic or inorganic acid may be used.
  • salts formed with the carboxylic acid group may be used.
  • alkali metal salts K, Na
  • alkaline earth metal salts Ca, Mg
  • any pharmaceutically acceptable, non-toxic salt may be used.
  • the Na- and Ca-salts are preferred.
  • esters of ortho-, meta- and para-salicylic acid are disclosed. Said esters are effective as ultra- violet ray screening compounds thereby rendering them ⁇ selves useful in preventing solar burning.
  • the disclosed meta- (or 5-) aminosalicylic esters and a number of related esters are also applicable in the composition according to the invention.
  • Applicable esters are e.g.
  • straight chain or branched ,-C, 8 alkyl esters e.g. methyl, ethyl, propyl, isopropyl, butyl, iso- butyl, amyl, hexyl, heptyl, octyl, nonyl, decyl, lauryl, myristyl, cetyl, and stearyl, etc.
  • alkenyl esters e.g. vinyl, allyl, undecenyl, oleyl, linolenyl, etc.
  • C ⁇ -Cg cycloalkyl esters e.g. cyclopropyl, cyclobutyl cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, etc. ,
  • aryl esters e.g. phenyl, toluyl, xylyl, naphthyl, etc.
  • alicyclic esters e.g. menthyl, etc.
  • aralkyl esters e.g. benzyl, phenethyl, etc.
  • the proper selection of the active ingredient depends on the selected type of formulation, the disease pattern, especially the site and type of the disease, and the desired release of the active ingredient, as shall be further expounded below
  • the physical state and solubility characteristics of the 5-ASA derivatives must be taken into account when selecting a suitable carrier composition for the -15 ingredient.
  • the preferred active ingredient at present is the free acid, 5-aminosalicylic acid.
  • a particularly interesting aspect of the invention is the use of the composition in the treatment of Crohn's disease.
  • SASP has not proved to be very effective, at least not in the most frequent case, where the disease is limited to the ileum.
  • the effective oral dose depends on the extent of the disease and for adults it usually amounts to 0 ⁇ 5 to 1.0 g twice a day. Generally about 20 mg/kg body weight of 5-ASA or a salt or ester thereof (calculated as 5-ASA) will be the recommended initial daily dosage subject to adjustment in accordance with the observed results of the treatment. In particular the dosage for children should be adjusted by means of serum concentration measurements.
  • 5-ASA and its derivatives can be formulated as ordinary oral drugs such as tablets or capsules by admixture with suitable pharmaceutical carriers which are well- known to the artisan, e.g. lactose, maize starch, potato starch, and lubricants, e.g. magnesium stearate and talc.
  • suitable pharmaceutical carriers which are well- known to the artisan, e.g. lactose, maize starch, potato starch, and lubricants, e.g. magnesium stearate and talc.
  • a preferred carrier constituent is a micro- crystalline cellulose having approximately the same
  • ⁇ 2 density as 5-ASA thereby preventing sedimentation and resulting heterogenicity during tablet production.
  • tablets in the form of slow-release tablets are preferred, but also enterosoluble tablets maybe used.
  • a particularly advantageous slow-release tablet has been developed the preparation of which is illustrated ' . in the following non-limiting example, based on the production of 1000 tablets containing 250 mg of the active ingredient. (All ingredients pharmaceutical grade) .
  • 270 g of microcrystalline cellulose and 60 g of potato starch are granulated with about 33 g of the above poly ⁇ vinylpyrrolidone solution to the same particle size.
  • the .resulting about 320 g of the coated granulate I are mixed with a lubricant mixture of 3 g of sodium stearate and 27 g of talc and with dry granulate II to form 650 g of total granulate which are pressed to form tablets with a diameter of 13.5 mm and a weight of 650 mg/tablet containing 250 mg of 5-ASA.
  • the resulting tablets were used in the clinical tests described below. As shown in the tests with ileostomy patients about 50% of the active ingredient is released in the small bowel, the remainder being available to the colon. By controlling the release a preparation with predominant effect versus Crohn's disease or colitis ulcerosa according to the site of the disease of the individual patient can be obtained.
  • the above formulation is believed to represent an effective com- promise applicable versus both diseases.
  • the release can be controlled by variating one or more of the following:
  • a relatively small particle size e.g. about 0.7 mm o ' r less and a relatively thin coating, e.g. by lowering the ethyl cellulose amount used or select a more permeable coating material, and an active ingredient with a good solubility at pH 7.5 which is the prevailing pH in the small bowel.
  • an active ingredient having a good solubility at pH 6 which is the prevailing pH in the colon and a greater particle size, e.g. about 1 mm or more, and a relatively thick coating.
  • solubility, acidity, and susceptibili ⁇ ty to hydrolysis of the different derivatives of 5-ASA such as acid addition salts, salts formed with the carboxylic group, e.g. alkali metal salts, alkaline earth metal salts, etc., and esters, e.g. alkyl, alkenyl, aryl, aralkyl, ⁇ ycloalkyl esters, etc.
  • acid addition salts e.g. alkali metal salts, alkaline earth metal salts, etc.
  • esters e.g. alkyl, alkenyl, aryl, aralkyl, ⁇ ycloalkyl esters, etc.
  • suitable pH-conditions might be established within the coated particles by adding to granulate I besides the active ingredient a suitable buffer in accordance with the desired release pattern.
  • the invention also relates to a method for the pre ⁇ paration of a sustained release tablet as defined in claim 9.
  • the tablet ingredients may also be variated. While the preferred organic solvent for the polyvinylpyrrolidone is isopropanol, other organic sulvents may also be used, as long as they do not in a significant degree act as solvents for the selected 5-ASA derivative.
  • Lr other coating agents may also be used, provided they secure the desired release pattern.
  • a number of other cellulose derivatives must be assumed to be applicable.
  • a sustained-release type tablet containing 250 mg of 5-ASA (Pentasa ⁇ -' ) . Only trace amounts of 5-ASA are released in the stomach at normal gastric pH. At pH 7.5 as is usual in the jejunum 5-ASA was released linearly in relation to time, all 5-ASA being released in 12 hours. At pH 6, the usual acidity of the colon, the release of 6-ASA from the tablet, was reduced. This unforeseeable and surprising release pattern should in principle ensure a continuous release of 5-ASA through the whole length of colon.
  • Each subject took two 5-ASA tablets, i.e. 500 mg 5-ASA, three times a day for six days, at 8 a.m., 4 p.m. and at midnight except for the first day, where the two first ingestions took place at 9 a.m. and 5 p.m.
  • the injec ⁇ tions are shown by arrows en fig. 5 and 6.
  • the two tablets at 8 a.m. were taken by the fasting subject.
  • Venous blood samples for determination of 5-ASA and 5-AcASA were drawn at intervals throughout the first day (fig. 5) and at 7.50 the following five days (i.e. before the 8 a.m. tablets were ingested) (fig. 6) .
  • ileostomy patients as well as the healthy volunteers filled in diary sheets concerning specified signs and symptoms (nausea, vomiting, headache, dizziness, visual and auditory sensations, abdominal pain or discomfort, constipation, diarrhoea, muscle-joint sensations and skin manifesta ⁇ tions) .
  • Blood pressure and pulse rate were monitored and on - as well as off - study analysis of hemoglobin, reticulocytes, thrombocytes, leucocytes, coagulation factors, S-alamine-amino-transferases, Se-urea, S- Creatinin together with urine analysis for albumin, glucose and sediment were carried out.
  • N 6 3 f 5 slow 6 3 1 fast
  • FIG. 1 A cumulative excretion rate of 5-ASA and 5-AcASA via ileostomy effluents from the individual subjects is shown in fig. 1.
  • Fig. 2 illustrates the ratios between free 5-ASA and 5-AcASA in the ileostomy secretions and 5-ASA still retained in the granules of the sustained-release preparation based on the mean values from fig. 1. From the figures is seen that no 5-ASA or 5-AcASA could be detected in ileostomy secretions during the first two hours. During the following hours free 5-ASA and 5-AcASA were registered in the effluents as they were excreted at constant rates up to 8 hours after ingestion of the tablets. At that time 58% of the ingested total dose was collected in the ileostomy bags.
  • Urinary excretions of free 5-ASA could not be recorded.
  • a mean of 737 mg 5-AcASA was excreted during 24 h (calculated as 5-ASA) .
  • the excretions ranged from 447 to 1304 mg per 24 h.
  • the 95% confidence limits of the mean value of 5-AcASA excretions were 587 - 887 mg per 24 h.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/DK1981/000027 1980-03-20 1981-03-20 Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration WO1981002671A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/371,123 US5013727A (en) 1980-03-20 1989-06-26 Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK120280 1980-03-20
DK1202/80 1980-03-20

Publications (1)

Publication Number Publication Date
WO1981002671A1 true WO1981002671A1 (en) 1981-10-01

Family

ID=8102129

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1981/000027 WO1981002671A1 (en) 1980-03-20 1981-03-20 Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration

Country Status (3)

Country Link
US (5) US4496553A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS57500432A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1981002671A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0083775A3 (en) * 1981-12-23 1984-11-28 Kurt Heinz Prof. Dr. Rer. Nat. Bauer Process for preparing 5-aminosalicylic acid drug compositions that dissolve well
EP0131485A3 (en) * 1983-07-07 1986-08-06 Rowell Laboratories Incorporated Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion : expanded range
US4664256A (en) * 1983-09-06 1987-05-12 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
EP0308665A3 (en) * 1981-12-23 1989-08-16 Kurt H. Prof. Dr. Bauer 5-aminosalicylic acid salts and pharmaceutical preparations containing them
USRE33239E (en) * 1983-09-06 1990-06-26 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
EP0383406A1 (en) * 1989-02-15 1990-08-22 Unilever N.V. A process for encapsulating an active ingredient
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
EP0398207A1 (en) * 1989-05-15 1990-11-22 Marion Merrell Dow Inc. Stable liquid form of 5-aminosalicylic acid
US4980173A (en) * 1980-03-20 1990-12-25 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
WO1992006690A1 (en) * 1990-10-22 1992-04-30 Borody Thomas J Treatment of non-inflammatory and non-infectious bowel disorders
GB2253346A (en) * 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
WO1992016214A1 (en) * 1991-03-15 1992-10-01 Norwich Eaton Pharmaceuticals Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
US5541171A (en) * 1981-07-31 1996-07-30 Tillotts Pharma Ag Orally administrable pharmaceutical composition
FR2760638A1 (fr) * 1997-03-14 1998-09-18 Astra Ab Formulation de balsalazide
CN1044364C (zh) * 1993-06-26 1999-07-28 河南师范大学 一种治疗肠炎和溃疡性结肠炎的药物及其制备工艺
WO2003032952A1 (en) * 2001-10-15 2003-04-24 Ferring Bv Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease
FR2831820A1 (fr) * 2001-11-05 2003-05-09 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
EP1470819A1 (en) * 2003-04-23 2004-10-27 Ferring B.V. High drug load mesalazine sachet
WO2004093884A3 (en) * 2003-04-23 2005-01-27 Ferring Bv High drug load mesalazine sachet
RU2286156C2 (ru) * 2001-10-15 2006-10-27 Ферринг Бв Способ приготовления фармацевтической композиции, включающей в себя 5-аминосалициловую кислоту, для применения в лечении неспецифического язвенного колита и болезни крона
US7790199B2 (en) 2003-11-14 2010-09-07 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
WO2011073245A2 (en) 2009-12-18 2011-06-23 Ferring B.V. Granules for pharmaceutical preparations, methods and apparatus for their production
US8282955B2 (en) 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
US10028917B2 (en) 2010-08-06 2018-07-24 Sofar Spa Beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and process for obtaining them
CN109568281A (zh) * 2018-12-21 2019-04-05 南京济群医药科技股份有限公司 一种柳氮磺胺吡啶片及其制备方法

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK536987A (da) * 1987-10-14 1989-04-15 Ferring Farma Lab Anvendelse af 5-aminosalicylsyre (5-asa) til fremstilling af et farmaceutisk praeparat til anvendelse ved reperfusionsbehandling
US5120306A (en) * 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
WO1991016057A1 (en) * 1990-04-18 1991-10-31 University Of Utah COLONIC-TARGETED ORAL DRUG-DOSAGE FORMS BASED ON CROSSLINKED HYDROGELS CONTAINING AZOBONDS AND EXHIBITING pH-DEPENDENT SWELLING
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
DK89592D0 (da) * 1992-07-07 1992-07-07 Helle Broendsted Laegemiddelafgivelsesindretning samt fremgangsmaade til fremstilling deraf
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US6028190A (en) * 1994-02-01 2000-02-22 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
US5637319A (en) * 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6004581A (en) * 1995-12-21 1999-12-21 Farmaceutisk Laboratorium Ferring A/S Modified release oral pharmaceutical composition and method for the treatment of bowel diseases
DK0871434T4 (da) * 1995-12-21 2008-04-07 Ferring Farma Lab Oralt farmaceutisk sammensætning med modificeret frigivelse indeholdende 5-ASA og fremgangsmåde til behandling af tarmsygdomme
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
ATE292961T1 (de) 1998-07-28 2005-04-15 Tanabe Seiyaku Co Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
US6114382A (en) * 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
EP1146862B1 (de) 1999-01-29 2003-04-23 Disphar International B.V. Pharmazeutische zusammensetzungen
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6589944B1 (en) * 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
DK1642885T3 (da) 2000-08-29 2010-01-04 Biocon Ltd Anvendelse af et farmaceutisk præparat der indeholder et para-aminophenyl-eddikesyrederivat til behandling af inflammatoriske tilstande i mave-tarmkanalen
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
EP2135611A1 (en) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
US7119079B2 (en) * 2003-01-22 2006-10-10 Barbeau Donald L Bioadhesive pharmaceutical compositions
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US8476233B2 (en) * 2003-08-29 2013-07-02 Therapeutic Research, Llc Methods for treatment for ulcerative colitis in mammals
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
EP1682114A2 (en) * 2003-10-27 2006-07-26 City of Hope Methods of lowering lipid levels in a mammal
EP1722630A4 (en) * 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
US20070213304A1 (en) 2004-02-06 2007-09-13 Thomas Borody Use of Aminosalicylates in Diarrhoea-Predominent Irritable Bowel Syndrome
DE602005022175D1 (de) * 2004-05-28 2010-08-19 Salix Pharmaceuticals Inc Prävention, behandlung und linderung strahlungsinduzierter enteritis
ES2565848T3 (es) 2004-07-07 2016-04-07 Biocon Limited Síntesis de compuestos inmunorreguladores unidos por grupos azoicos
EP2471536A1 (en) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroid analogs and characterization and treatment methods
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US7498355B2 (en) * 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US20090017110A1 (en) * 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102670626A (zh) * 2005-08-24 2012-09-19 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP4753851B2 (ja) * 2005-12-19 2011-08-24 日本碍子株式会社 窒化アルミニウム粉末、窒化アルミニウム質セラミックス焼結体、半導体製造装置用部材、窒化アルミニウム発光材料、及び窒化アルミニウム粉末の製造方法
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
US7964585B2 (en) * 2006-03-14 2011-06-21 Case Western Reserve University Composition and method of treating peripheral neuropathy
KR20090021346A (ko) * 2006-06-06 2009-03-03 안티브 테라퓨틱스 인크. 트리메부틴 및 ｎ-데스메틸 트리메부틴 염
FR2908600B1 (fr) * 2006-11-21 2009-01-02 Axiss France Sas Soc Par Actio Capsicum microencapsule, procede pour sa preparation, et utilisation
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
EP2334178A4 (en) * 2008-10-03 2012-04-11 Falk Pharma Gmbh COMPOSITIONS AND METHODS OF TREATING THERAPEUTIC DISEASES WITH GRANULATED MESALAMINE
US20160193343A1 (en) * 2013-06-10 2016-07-07 Aihol Corporation Composition for use in treating and preventing inflammation related disorder
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US20150164920A1 (en) 2012-03-30 2015-06-18 Laboratorios Del Dr. Esteve S.A. Controlled release formulation comprising mesalamine
US9738631B2 (en) 2012-05-07 2017-08-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
JP2015522531A (ja) 2012-05-07 2015-08-06 セリックスビオ プライヴェート リミテッド 神経筋疾患及び神経変性疾患の治療のための組成物及び方法
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175359A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
CA2873096A1 (en) 2012-05-23 2013-11-28 Cellixbio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
EP2892878A4 (en) 2012-09-08 2016-02-24 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND LIPID DISORDER
EP2916818B1 (en) 2012-11-09 2017-02-01 Scidose LLC Enema composition for treatment of ulcerative colitis having long term stability
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
SG11201706952VA (en) 2014-09-26 2017-10-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en) 2014-09-29 2020-03-18 Cellix Bio Private Limited Compounds and compositions for the treatment of multiple sclerosis
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
US20190256915A1 (en) * 2016-09-14 2019-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of diagnosing and treating cd55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (chaple), a newly identified orphan disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB722795A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) *
CH342965A (de) * 1955-03-31 1959-12-15 Daniewski Wlodzimierz Doc Mgr Verfahren zur Reinigung von 5-Amino-salizylsäure
FR2267088A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1974-04-11 1975-11-07 Auburn Res Found
DE2712934A1 (de) * 1977-04-01 1978-10-05 Mundipharma Ag Mittel, insbesondere gegen hautschaeden durch ultraviolette strahlung, sowie verfahren zu seiner herstellung
GB2021409A (en) * 1977-05-25 1979-12-05 Fisons Ltd Pharmaceutical composition

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
US2928769A (en) * 1957-07-22 1960-03-15 Strong Cobb And Company Inc Production of controlled release medicaments
US3017329A (en) * 1957-08-15 1962-01-16 Dow Chemical Co Method of locating enteric constrictions with a plurality of pills containing an x-ray contrast agent
US3039933A (en) * 1957-10-07 1962-06-19 Premo Pharmaceutical Lab Inc Ethyl cellulose-polyethylene glycol tablet matrix
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3043747A (en) * 1958-10-22 1962-07-10 Upjohn Co Tablets coated with carboxymethylcellulose shellac composition
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US3062720A (en) * 1959-05-20 1962-11-06 Philips Roxane Sustained release pharmaceutical tablet
US2951792A (en) * 1959-11-18 1960-09-06 Smith Kline French Lab Sustained release pharmaceutical tablets
US3054724A (en) * 1960-05-12 1962-09-18 Smith Kline French Lab Coloring discrete solids and compositions therefor
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
NL122039C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1960-10-20
US3108046A (en) * 1960-11-25 1963-10-22 Smith Kline French Lab Method of preparing high dosage sustained release tablet and product of this method
US3133863A (en) * 1961-03-10 1964-05-19 Strong Cobb Arner Inc Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
US3078216A (en) * 1961-04-11 1963-02-19 American Cyanamid Co Prolonged release oral pharmaceutical preparations
NL283570A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1961-09-25
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
US3388041A (en) * 1964-01-27 1968-06-11 Richardson Merrell Inc High dosage sustained release tablet
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3906086A (en) * 1971-07-19 1975-09-16 Richard G Powers Timed-release aspirin
GB1423985A (en) * 1972-02-15 1976-02-04 Fisons Ltd Pharmaceutical compositions containing bischromonyloxy compounds
US3950521A (en) * 1972-05-22 1976-04-13 Interx Research Corporation Administration of alkali metal salicylamide salts
GB1509979A (en) * 1975-11-28 1978-05-10 Fisons Ltd Pharmaceutical compositions containing aspirin or indomethacin
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
US4211777A (en) * 1977-11-25 1980-07-08 Fisons Limited Compositions comprising a compound having sodium cromoglycate activity and aminosalicylic acid
US4221810A (en) * 1978-03-23 1980-09-09 Nisshin Flour Milling Co., Ltd. Antiulcer compounds
US4440754A (en) * 1978-05-30 1984-04-03 Sorenson John R J Anti-inflammatory and anti-ulcer compounds and process
US4190716A (en) * 1978-12-20 1980-02-26 Dynapol Polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4298595A (en) * 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4440765A (en) * 1979-07-23 1984-04-03 William H. Rorer, Inc. Amidinoureas
US4350689A (en) * 1980-02-15 1982-09-21 American Cyanamid Company Combinations of agents which give enhanced anti-inflammatory activity
WO1981002671A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration
WO1981002672A1 (en) * 1980-03-20 1981-10-01 Ferring Farma Lab Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease
SE8002322L (sv) * 1980-03-26 1981-09-27 Pharmacia Ab Medel for behandling av inflammatoriska tarmsjukdomar
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
DE3027013A1 (de) * 1980-07-17 1982-02-18 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin Mittel zur behandlung von colitis ulcerosa, enteritis regionalis crohn (morbus crohn), chronischer unspezifischer colitis und divertikulitis sowie verwendung von salicylazobenzoesaeure, zur herstellung von derartigen mitteln
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4312806A (en) * 1981-03-02 1982-01-26 G. D. Searle & Co. Method and compounds for treating inflammatory bowel disease
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
EP0066423B1 (en) * 1981-05-29 1988-01-13 Britoil Plc Method of determining the signatures of arrays of marine seismic sources, and of accumulating data for use in such methods
US4374932A (en) * 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4489197A (en) * 1981-11-09 1984-12-18 Dynapol Polymeric active methylene compounds
US4526933A (en) * 1981-11-09 1985-07-02 Dynapol Polymeric active methylene compounds, their preparation and their use in azo polymers
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
SE8303399D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Azo-bis-salicyl syra och salt derav, deras farmaceutiska beredning samt framstellning av syran
DE3323702A1 (de) * 1983-07-01 1985-01-10 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin 5-aminosalicylsaeure-o-sulfate von physiologisch unbedenklichen basen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4539198A (en) * 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
US4664256A (en) * 1983-09-06 1987-05-12 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
US4657900A (en) * 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US4663308A (en) * 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
US4851443A (en) * 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
DE3668450D1 (de) * 1985-03-14 1990-03-01 Smithkline Dauelsberg 5-aminosalicylsaeurederivate von nicht-steroidalen entzuendungshemmenden sauren.
EP0207638B1 (en) * 1985-06-04 1990-12-19 Teijin Limited Sustained-release pharmaceutical preparation
IT1230630B (it) * 1988-11-11 1991-10-28 Eniricerche Spa Procedimento per la preparazione di un precursore di zirconio biossido

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB722795A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) *
CH342965A (de) * 1955-03-31 1959-12-15 Daniewski Wlodzimierz Doc Mgr Verfahren zur Reinigung von 5-Amino-salizylsäure
FR2267088A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1974-04-11 1975-11-07 Auburn Res Found
DE2712934A1 (de) * 1977-04-01 1978-10-05 Mundipharma Ag Mittel, insbesondere gegen hautschaeden durch ultraviolette strahlung, sowie verfahren zu seiner herstellung
GB2021409A (en) * 1977-05-25 1979-12-05 Fisons Ltd Pharmaceutical composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Gastroenterology, Volume 64, no. 2, issued 1973, (Baltimore), M.A. Peppercorn and P. Goldman: "Distribution studies of salizylazosulfapyridine and its metabolites", pages 240-245 *
Journal of Pharmaceutical Sciences, Volume 68, no. 10, issued 1979, October (Washington), H.J. Pieniaszek Jr, and T.R. Bates: "Capacitylimited gut wall met abolism of 5-aminosalicyclic acid, a therapeutically active metabolite of sulfasalazine, in rats", pages 1323-1325 *
Scandinavian Journal of Gastroenterology, Volume 15, no. 6, issued 1980, September (Oslo) C.P. Willoughby et al:, "The effect of topical N-acetyl-5-aminosalicyclic acid in ulcerative colitis", pages 715-719 *
The Lancet, issued 1977, October 29, (London), A.K. Azad Khan et al: "An experiment to determine the active therapeutic moiety of sulphasalazine", pages 892-895 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041431A (en) * 1980-03-20 1991-08-20 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4980173A (en) * 1980-03-20 1990-12-25 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US5013727A (en) * 1980-03-20 1991-05-07 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US5541170A (en) * 1981-07-31 1996-07-30 Tillotts Pharma Ag Orally administrable pharmaceutical compositions
US5541171A (en) * 1981-07-31 1996-07-30 Tillotts Pharma Ag Orally administrable pharmaceutical composition
US4699902A (en) * 1981-12-23 1987-10-13 Bauer Kurt H Process for the production of readily soluble 5-aminosalicylic acid preparations
US4540685A (en) * 1981-12-23 1985-09-10 Bauer Kurt H Process for the production of readily soluble 5-aminosalicylic acid preparations, compositions and methods of use
EP0308665A3 (en) * 1981-12-23 1989-08-16 Kurt H. Prof. Dr. Bauer 5-aminosalicylic acid salts and pharmaceutical preparations containing them
EP0083775A3 (en) * 1981-12-23 1984-11-28 Kurt Heinz Prof. Dr. Rer. Nat. Bauer Process for preparing 5-aminosalicylic acid drug compositions that dissolve well
EP0131485A3 (en) * 1983-07-07 1986-08-06 Rowell Laboratories Incorporated Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion : expanded range
US4664256A (en) * 1983-09-06 1987-05-12 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
USRE33239E (en) * 1983-09-06 1990-06-26 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
EP0383406A1 (en) * 1989-02-15 1990-08-22 Unilever N.V. A process for encapsulating an active ingredient
EP0398207A1 (en) * 1989-05-15 1990-11-22 Marion Merrell Dow Inc. Stable liquid form of 5-aminosalicylic acid
WO1992006690A1 (en) * 1990-10-22 1992-04-30 Borody Thomas J Treatment of non-inflammatory and non-infectious bowel disorders
US5401512A (en) * 1991-02-22 1995-03-28 Rhodes; John Delayed release oral dosage forms for treatment of intestinal disorders
GB2253346A (en) * 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
WO1992016214A1 (en) * 1991-03-15 1992-10-01 Norwich Eaton Pharmaceuticals Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
CN1044364C (zh) * 1993-06-26 1999-07-28 河南师范大学 一种治疗肠炎和溃疡性结肠炎的药物及其制备工艺
US6197341B1 (en) 1997-03-14 2001-03-06 Stefan Friess Formulations of balsalazide and its derivatives
GR980100096A (el) * 1997-03-14 1998-11-30 Astra Aktiebolag Νεα συνθεση βαλσαλαζιδης
NL1008575C2 (nl) * 1997-03-14 1999-09-10 Astra Ab Nieuwe formulering.
BE1011837A5 (fr) * 1997-03-14 2000-02-01 Astra Ab Nouvelle composition de balsalazide.
FR2760638A1 (fr) * 1997-03-14 1998-09-18 Astra Ab Formulation de balsalazide
KR100859358B1 (ko) * 2001-10-15 2008-09-22 훼링 비.브이. 궤양성 대장염 및 크론병의 치료에 유용한5-아미노살리실산을 포함하는 약학적 조성물의 제조 방법
RU2286156C2 (ru) * 2001-10-15 2006-10-27 Ферринг Бв Способ приготовления фармацевтической композиции, включающей в себя 5-аминосалициловую кислоту, для применения в лечении неспецифического язвенного колита и болезни крона
US8282955B2 (en) 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
WO2003032952A1 (en) * 2001-10-15 2003-04-24 Ferring Bv Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease
FR2831820A1 (fr) * 2001-11-05 2003-05-09 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
WO2003039520A1 (fr) * 2001-11-05 2003-05-15 Ethypharm Comprime orodispersible presentant une grande homogeneite et son procede de preparation
EP1470819A1 (en) * 2003-04-23 2004-10-27 Ferring B.V. High drug load mesalazine sachet
WO2004093884A3 (en) * 2003-04-23 2005-01-27 Ferring Bv High drug load mesalazine sachet
JP2006524207A (ja) * 2003-04-23 2006-10-26 フェリング ベスローテン フェンノートシャップ 薬効を有する医薬の含有割合が高いメサラジンサッシェ
AU2004231316B2 (en) * 2003-04-23 2008-02-21 Ferring B.V. High drug load mesalazine sachet
US8858992B2 (en) 2003-04-23 2014-10-14 Ferring B.V. High drug load mesalazine sachet
EP2756844A1 (en) * 2003-04-23 2014-07-23 Ferring B.V. High drug load mesalazine sachet
US7820203B2 (en) 2003-11-14 2010-10-26 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US7829121B2 (en) 2003-11-14 2010-11-09 Eurand Inc. Modified release dosage forms of skeletal muscle relaxants
US7790199B2 (en) 2003-11-14 2010-09-07 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US8877245B2 (en) 2003-11-14 2014-11-04 Aptalis Pharmatech, Inc. Modified release dosage forms of skeletal muscle relaxants
US9375410B2 (en) 2003-11-14 2016-06-28 Adare Pharmaceuticals, Inc. Modified release dosage forms of skeletal muscle relaxants
US9399025B2 (en) 2003-11-14 2016-07-26 Adare Pharmaceuticals, Inc. Modified release dosage forms of skeletal muscle relaxants
EP2340812A1 (en) 2009-12-18 2011-07-06 Ferring International Center S.A. Granules for pharmaceutical preparations, methods and apparatus for their production
WO2011073245A2 (en) 2009-12-18 2011-06-23 Ferring B.V. Granules for pharmaceutical preparations, methods and apparatus for their production
EP2512453B1 (en) 2009-12-18 2016-11-09 Ferring B.V. Granules for pharmaceutical preparations, methods and apparatus for their production
US10028917B2 (en) 2010-08-06 2018-07-24 Sofar Spa Beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and process for obtaining them
EP3009130B1 (en) * 2010-08-06 2018-10-10 SOFAR S.p.A. Beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres
CN109568281A (zh) * 2018-12-21 2019-04-05 南京济群医药科技股份有限公司 一种柳氮磺胺吡啶片及其制备方法
CN109568281B (zh) * 2018-12-21 2022-05-10 南京济群医药科技股份有限公司 一种柳氮磺胺吡啶片及其制备方法

Also Published As

Publication number Publication date
US4980173A (en) 1990-12-25
US4496553A (en) 1985-01-29
US4880794A (en) 1989-11-14
JPS57500432A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-03-11
US4496553B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1988-06-28
US5041431A (en) 1991-08-20
US5013727A (en) 1991-05-07

Similar Documents

Publication Publication Date Title
US5041431A (en) Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
US4960765A (en) Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
FI85216C (fi) Foerfarande foer farmstaellning av ett oralt administrerbart farmaceutisk preparat av 5-amino-salicylsyra.
CA2140254C (en) Controlled release morphine preparation
US4900558A (en) Sustained release ibuprofen formulation including a core of ibuprofen and a microcrystalline cellulose and a covering of acrylic polymer and hydroxylated cellulose derivative
US20150150797A1 (en) Pellet formulation for the treatment of the intestinal tract
CA1273876A (en) Theophylline sustained release tablet
Pullan et al. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.
Oosterhuis et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose.
SK284539B6 (sk) Použitie nikotínu, farmaceutické kompozície a farmaceutický kombinačný produkt
McDermott et al. The absorption, excretion, and destruction of orally administered penicillin
PT624371E (pt) Microcapsulas para a libertacao controlada de acido acetilsalicilico
JP2014058542A (ja) アルコール摂取症状を軽減するための方法
JPS60158197A (ja) 抗生物質およびその製法
JP3018160B2 (ja) 月経困難症及び／又は月経前症候群の軽減用薬剤
RU98111765A (ru) Фармацевтическая композиция для орального введения с модифицированным высвобождением, содержащая 5-аск, и способ лечения кишечных заболеваний
WO1992016206A1 (en) The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
EP0386023A1 (en) Sustained-release nifedipine formulation
Christensen et al. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations
Stoll et al. In vitro dissolution and in vivo absorption of nitrofurantoin from deoxycholic acid coprecipitates
WO1981002672A1 (en) Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease
US3784683A (en) Tablet preparation
US5034379A (en) Pharmaceutical formulation containing azapropazone
Riley et al. Delayed‐release mesalazine (5‐aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.
CA2190750A1 (en) Arteriosclerosis depressant

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): DE DK GB JP NL SU US